For Safety. An employee whose assignment requires work at a District work site and who does 44 not fit within the conditions of paragraphs 1-8 above, may choose to access any or all of the 45 following benefits under the terms of the applicable collective bargaining agreement (CBA) or 46 law:
For Safety. Jazz may terminate effective immediately upon written notice to Codiak in the event of:
(a) withdrawal or suspension of any Regulatory Approval for a Licensed Product in the United States, Japan or a Major European Country;
(b) a Regulatory Authority notifies Jazz or its Affiliate that there is a safety issue regarding any Licensed Compound or Licensed Product; or.
(c) Jazz in good faith determines that it is not advisable to continue to Develop or Commercialize any Licensed Compound or Licensed Product as a result of a safety concern regarding the use thereof for the Indication to which such Licensed Compound or Licensed Product is directed, based on specific results generated in connection with the Development conducted hereunder by either Party, safety reports, evidence provided in scientific publications or other objective evidence from credible sources.
For Safety. AbbVie may terminate this Agreement, in its entirety or on a Licensed Product-by-Licensed Product basis, effective immediately upon written notice to Caribou if AbbVie in good faith believes that it is not advisable for AbbVie to continue to Exploit the Collaboration CAR-T Product(s) or Licensed Product(s) as a result of a perceived serious safety issue regarding the use of any Collaboration CAR-T Product or Licensed Product.
For Safety. Sanofi may terminate this Agreement solely with respect to the affected Research Program, Sanofi Target or Licensed Product, effective immediately upon written notice to Ablynx, as follows: [...***...
For Safety. Sanofi will have the right to terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis, upon [***] prior written notice to RevMed, due to safety concerns raised by a Regulatory Authority, an Institutional Review Board for a Clinical Trial or by Sanofi’s internal regulatory decision makers acting in accordance with Sanofi’s standard internal policies (any such entity or group, a “Safety Reviewer”), where such Safety Reviewer recommends cessation of Development or Commercialization of such SHP2 Inhibitor or Product with respect to any SHP2 Inhibitor or Product (and a summary of such concerns will be stated in the notice of termination). During such [***] notice period, each Party will continue to perform all of its obligations under this Agreement then in effect.
For Safety. 12 An employee whose assignment requires work at a District work site and who does not fit 13 within the conditions of paragraphs 2-6 above, may choose to access any or all of the following 14 benefits under the terms of the applicable collective bargaining agreement (CBA) or those that 15 may be available to them by law:
16 a. Personal leave and/or vacation leave.
17 b. Unpaid leave of absence. 19 Employees who allege their workplace is unsafe are encouraged to immediately report their 20 concerns to their supervisor and/or the workplace safety committee. Such employees may in 21 limited circumstances also have recourse through the Department of Labor & Industries under 22 WAC 000-00-000.
For Safety. MyoKardia may terminate this Agreement in its entirety or on a Target-by-Target, Product-by-Product or Molecule-by-Molecule basis, effective immediately upon written notice to Fulcrum in the event of:
(a) withdrawal or suspension of any Regulatory Approval for a Product directed against a Target in a Major Market Country;
(b) a Regulatory Authority notifies MyoKardia or its Affiliate that there is a safety issue regarding any Molecule or Product directed against a Target; or
(c) MyoKardia in good faith determines that it is not advisable to continue to develop or commercialize any Product directed against a Target as a result of a safety concern regarding the use thereof for the indication to which such Product is directed, based on specific results generated in connection with the development conducted hereunder by either Party, safety reports, evidence provided in scientific publications or other objective evidence from credible sources.
For Safety. Otsuka shall have the right to terminate this Agreement in its entirety immediately upon written notice to Aurinia if: (i) Otsuka reasonably determines, based upon additional information that becomes available or an analysis of the existing information at any time (including based upon preclinical safety data, such as data from animal toxicology studies, or the observation of serious adverse effects in humans after a Product has been administered to humans, such as during a Clinical Trial or after the First Commercial Sale), that it would be incompatible with the welfare of patients to continue to Develop or Commercialize such Product; (ii) substantially all ongoing Clinical Trials of a Product are ordered or required to be terminated by one or more Regulatory Authorities in the Otsuka Territory; or (iii) any Regulatory Approval for a Product in the Aurinia Territory or the Otsuka Territory is withdrawn.
For Safety. 38 An employee whose assignment requires work at a District worksite and who does not fit 39 within the conditions of Sections 1-8, above, may choose to access any or all of the following 40 benefits under the terms of the CBA or law: Personal leave or vacation, if available. 41 Employees who allege their workplace is unsafe are encouraged to immediately report their 42 concerns to their supervisor and/or the workplace safety committee. Such employees may in 43 limited circumstances also have recourse through L&I under WAC 000-000-000. Nothing 44 about this section limits an employee from requesting a leave of absence under Section 9.8 45 of the CBA.
For Safety. Any regular seniority employee(s) who performs his/her job in a manner which results in injury to persons or serious damage to equipment or property will constitute reasonable suspicion to believe that such individual was under the influences of drugs or alcohol. Such reasonable suspicion will become probable cause to test such individuals in accordance with the Policy, except that in the case of injury when medical treatment beyond first aid is not required and no other symptoms of drug or alcohol use are present.
